Congress is unlikely to move psilocybin or MDMA out of the most restricted drug category in 2026, but smaller bills focused on research and helping veterans access these treatments are gaining ground. This is a politically easier move — lawmakers can say they support helping veterans without fully endorsing psychedelics for everyone. For patients, it means slow, incremental progress rather than a big policy shift.
Consensus of 4 agents: legislator, dea_officer, fda_reviewer. 1 dissenting.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →